key: cord-1044443-ve5g5opd
authors: Ohashi, Hirofumi; Hishiki, Takayuki; Akazawa, Daisuke; Kim, Kwang Su; Woo, Joohyeon; Shionoya, Kaho; Tsuchimoto, Kana; Iwanami, Shoya; Moriyama, Saya; Kinoshita, Hitomi; Yamada, Souichi; Kuroda, Yudai; Yamamoto, Tsukasa; Kishida, Noriko; Watanabe, Shinji; Hasegawa, Hideki; Ebihara, Hideki; Suzuki, Tadaki; Maeda, Ken; Fukushi, Shuetsu; Takahashi, Yoshimasa; Iwami, Shingo; Watashi, Koichi
title: Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
date: 2022-02-28
journal: bioRxiv
DOI: 10.1101/2022.02.27.482147
sha: ede108538033ae00d1667685afbd488380020613
doc_id: 1044443
cord_uid: ve5g5opd

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence’s impact on choosing optimal drug treatment.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (lineage B.1.1.529) has rapidly spread worldwide and become the most prevalent SARS-CoV-2 in many countries (Elliott et al., 2022; Viana et al., 2022) . Of the identified Omicron subvariants, the subvariant BA.1 was dominantly prevalent in the early days after Omicron emerged from November 2021. However, the replacement of BA.1 with another subvariant, BA.2, has grown in the countries, including Denmark, UK, and South Africa, alerting a higher transmission of this new subvariant worldwide that can prolong the current wave of COVID-19 (USKH, 2022). The BA.1 and BA.2 have more than 30 shared amino acid substitutions from the Wuhan strain, especially with approximately 20 shared mutations in the Spike protein. They also have some unique mutations ( Figure 1 ). For example, the S1 69-70 deletion as a hallmark of BA.1, associated with S-gene target failure in PCR tests, is unconserved in BA.2 (WHO, 2021; Majumdar and Sarkar, 2021) . BA.2 also has four unique substitutions (S371F, T376A, D405N, and R408S) compared with BA.1, with lacking three mutations (S371L, G446S, and G496S) in the receptorbinding domain of the S1, which is involved in vaccine and antibody responses (Majumdar and Sarkar, 2021) . Such unique mutation patterns in BA.1 and BA.2 possibly affect their sensitivities to approved drugs/antibodies against COVID-19. Therefore, we quantified such drug/antibody responses of BA1 and BA.2 compared to other variants of concern (Alpha, Gamma, Delta) and a Wuhan strain in cell culture infection assays. Furthermore, most reports have so far evaluated only 50% (or 90%) inhibitory concentrations to quantify the drug activity. Yet, these concentrations are pharmacologically not the sole factor that determines antiviral efficacy. Thus, we also estimated the slopes of dose-response sigmoid curves to quantitatively discuss their drug effects at clinical drug concentrations (Koizumi et al., 2017; Shen et al., 2008) .

We evaluated the intrinsic sensitivity of SARS-CoV-2 variants (Wuhan, Alpha, Gamma, Delta, Omicron-BA.1, and Omicron-BA.2) to the approved antibodies/drugs [casirivimab, imdevimab, S309 (the prototype antibody of sotrovimab), EIDD-1931 (the active form of molnupiravir), and nirmatrelvir]. Each SARS-CoV-2 strain was inoculated and cultivated in VeroE6/TMPRSS2 cells upon treatment with varying concentrations of antibodies/drugs (up to 4-10 µM or µg/mL) to measure viral RNA in the culture supernatant, as well as cell viability at 24 h postinoculation (Matsuyama et al., 2020) . Figure 2 shows the dose-response curve of each variant against tested antibodies/drugs ( Figure 2 ).

No cytotoxicity induced by antibody/drug was observed in all tested concentrations ( Figure S1 ). Overall, inhibition potency of the three tested antibodies, casirivimab, imdevimab, and S309 to Omicron subvariants BA.1 and BA.2, were severely impaired, in contrast to their outstanding activities against the Wuhan strain and Alpha, Gamma, and Delta variants (Figure 2A -C). Casirivimab did not show any antiviral activity to BA.1 and BA.2 up to 10 µg/ml ( Figure 2A) . Also, imdevimab lost its activity to BA.1, but retained a minor antiviral activity to reduce BA.2 infections ( Figure 2B ). S309's antiviral activity to BA.1 was more modest than that of other variants, and that to BA.2 was even weaker ( Figure 2C ). These tendencies of the IC50 shifts between BA.1 and other variants (Table. 1 

Based on the dose-response curves, we quantified the concentrations that achieved 50% and 90% of the maximal effect (IC50, IC90). Additionally, we estimated the Hill coefficient (m) ( Although IC50 (or IC90) is frequently used to evaluate the "potency" of drugs, the "efficacy" of drugs is determined by both m and IC50: The inhibition of viral propagation ("drug efficacy") at any given drug concentration (D) can be expressed as the instantaneously inhibitory potential (IIP) (Koizumi et al., 2017; Shen et al., 2008) .

Here IIP indicates the log of viral reduction. Since antiviral drugs are usually at far higher concentrations than IC50 in clinical settings, the high steepness of the sigmoid curve (high m) achieves a much higher IIP than those having low steepness (low m) even if IC50 is the same. Hence, since sequence substitutions in the drug target [Spike, main protease (NSP5), or polymerase (NSP12)] can change IC50 and m, we estimated these values based on the dose-response curve for each variant through the fitting of fu with nonlinear least squared regression (Table 1) . To evaluate the antiviral effect in clinical drug concentrations, we calculated IIP at maximum drug concentrations [IIP(Cmax)] for each antibody/drug against each variant (Table 1 and Table S1 ) based on available pharmacokinetics in patients. Although casirivimab conserved IC50 and m (within two folds) among the Wuhan, Alpha, Gamma, and Delta strains, with profound effects to reduce viral propagation at Cmax (3.67-7.00 log), its activity was lost to BA.1 and BA.2. While imdevimab also had a conserved antiviral effect at Cmax (4.52-7.97 log) to the variants other than Omicron, its effect was lost on BA.1, and was retained moderately on BA.2 (2.17 log). S309's effect at Cmax on these variants other than BA.2 was high (> 3 log), but that on BA.2 was estimated to be lower than others (1.15 log). In contrast, the IC50 and m for EIDD-1931 against each variant were less diverse (within two folds) to conserve strong antiviral effects at Cmax (1.97-3.53 log). Nirmatrelvir had an even more conserved IC50 and m, with similar IIP at Cmax (0.753-0.986). These analyses suggest that while the three approved-antibodies were less active to BA.1 and BA.2, EIDD-1931 and nirmatrelvir had conserved antiviral effects on variants. Our analysis suggests that the emergence of SARS-CoV-2 variants narrowed the options for efficient antibody treatments.

This study was limited to cell culture infection assays, in which cell types and other conditions reflected drug sensitivities. However, viral targeting agents examined in this study (casirivimab, imdevimab, and S309 target Spike, EIDD-1931 target polymerase, and nirmatrelvir target main protease) were much less governed through cellular backgrounds, compared to host-targeting antivirals, and instead are more affected by viral factors such as sequence changes in the viral genome. Our assay at least compared the intrinsic antibody/drug sensitivity of SARS-CoV-2 variants side by side, helpful in discussing the impact of sequence substitutions on antibody/drug activities.

Additionally, the analyses of animal and patient infections under treatment were further desired to understand drug efficacy. Yet, given the Omicron BA.2 wave's urgency and the need for the scientific evidence to better combat this infectious disease, our data significantly present the potential diversity of drug/antibody efficacies among SARS-CoV-2 variants.

VeroE6 

The authors declare no competing interests.

VeroE6/TMPRSS2 cells, a VeroE6 cell clone overexpressing the transmembrane protease, serine 2 (TMPRSS2), were cultured in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Sigma), 100 units/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES (pH 7.4), and 1 mg/mL G418 (Nacalai) at 37˚C in 5% CO2 (Ohashi et al., 2021) .

inoculation, we used WK-521 (Wuhan strain, EPI_ISL_408667), QK002 (Alpha, EPI_ISL_768526), TY7-501 (Gamma, EPI_ISL_833366), TY11-927 (Delta, EPI_ISL_2158617), TY38-873 (Omicron BA.1, EPI_ISL_7418017), and TY40-385 (Omicron BA.2, EPI_ISL_9595859) strains, isolated from COVID-19 patients and registered in GISAID.

Viral infectious titers were measured by inoculating VeroE6/TMPRSS2 cells with a 10-fold serial dilution of the virus followed by measuring cytopathology to calculate TCID50/ml (Ohashi et al., 2021) . Infection assay was conducted by inoculating VeroE6/TMPRSS2 cells with each SARS-CoV-2 strain at an MOI of 0.003 for 1 h, followed by washing out free viruses and culturing cells with fresh medium. A medium with 2% FBS without G418 was used during the infection assay. Antibodies and antiviral drugs were treated for 1 h during virus inoculation and 24 h after inoculation. At 24 h postinfection, the culture supernatant was recovered to isolate RNA using MagMax Viral/Pathogen Nucleic Acid Isolation kit (Thermo Fisher Scientific) and quantify SARS-CoV-2 RNA by real time RT-PCR with a one-step qRT-PCR kit (THUNDERBIRD Probe One-step qRT-PCR kit, TOYOBO) using 5'-ACAGGTACGTTAATAGTTAATAGCGT-3', 5'-ATATTGCAGCAGTACGCACACA-3', and 5'-FAM-ACACTAGCCATCCTTACTGCGCTTCG-TAMRA-3'. Simultaneously, cell viability was quantified by fixing the cells with 4% paraformaldehyde and staining with DAPI to count the number of cells using a high content imaging system ImageXpress (Molecular Devices). 1.7, P.1, B.1.617.2, BA.1, and BA.2 lineage in NSP5, NSP12, 

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Rapid increase in Omicron infections in England during December 2021: REACT-1 study

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Mutational and phylogenetic analyses of the two lineages of the Omicron variant

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

SARS-CoV-2 variants of concern and variants under investigation in England

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern